Search results
Results From The WOW.Com Content Network
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6] [7] [8] [4] It is also used for the treatment of eosinophilic esophagitis, [9] prurigo nodularis [10] and ...
macular degeneration (wet form) Raxibacumab [39] mab: human: anthrax toxin, protective antigen: Y: anthrax (prophylaxis and treatment) Ravagalimab [5] mab: humanized: CD40: Crohn's disease Ravulizumab [26] Ultomiris: mab: humanized: C5: Y: paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome: Refanezumab: mab: humanized ...
As of 2022, Caremark Rx, Express Scripts, OptumRx, Humana, Prime Therapeutics, and MedImpact Healthcare Systems were the six largest public PBMs that control 95% of the market, while the top three controlled 80% of the market. [41] As of 2024, the top 3 controlled a market of almost $600 billion. [6]
However, mAbs are large molecules and due to the blood–brain barrier, uptake of mAb into the brain is extremely limited, only approximately 1 of 1000 mAb molecules is estimated to pass. [25] However, the Peripheral Sink hypothesis proposes a mechanism where mAbs may not need to cross the blood–brain barrier. [ 26 ]
Drug and Therapeutics Bulletin is a monthly scientific journal with evaluations of, and practical advice on, individual treatments and the overall management of disease. The journal is published by the BMJ Group and as a founder member of The International Society of Drug Bulletins, the journal is also completely independent of the pharmaceutical industry, government and regulatory authorities ...
F1000 (formerly "Faculty of 1000") is an open research publisher for scientists, scholars, and clinical researchers. F1000 offers a different research evaluation service from standard academic journals by offering peer-review after, rather than before, publishing a research article. [ 1 ]
Rank Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013 Company(ies) Disease/Medical Use First Approval Date Patent Expiration Date [6] [7]; 1: Abilify
Prior to approval, each drug marketed in the United States must go through a detailed FDA review process. In 1992, under the Prescription Drug User Fee Act (PDUFA), FDA agreed to specific goals for improving the drug review time and created a two-tiered system of review times – standard review and priority review.